Investment Q&A

Q: This Health Care ETF has an unusually high yield. Why? Is it because of return of capital or some other source?

Q: Good morning 5i Team

This is a general question about secondary share offerings like the one issued by Savaria recently. In coming up with the offering price, is it typically based on a fundamental analysis of the corporations value or is it just a negotiated discount to the current market price?

Thanks as always.
Peter

Q: Good Morning
Is this deal with SIS today a positive ? Is the family involvement in this deal a positive development for the company ?
Thank You
Clarence

Q: In mid Feb, IRTC reported another strong quarter and issued a better than expected 2019 guidance. However, about a month later a (short?) report stated that the main IRTC product could face a Medicare reimbursement cut of 45-65%, possibly by the latter half of 2021. Do you know if IRTC has publicly addressed this issue? Whether IRTC has or has not done so, is it wise to simply exit the position and move on to another health care stock? Thanks in advance for your input. James.

Q: Following close scrutiny of the available information to date, I have decided to support Johnathan Goodman in his battle with Medison. This is essentially a war between two men as no one else at Knight or Medison has more than 35000 shares (one person) and the rest have basically none. Goodman has double the number as Medison. I predict Goodman will add to his position before May 7 - he could afford as many shares as he wants/needs to succeed.
However, kudos to Jakobsohn, despite my extreme cynicism towards his motives - he will control the 28% of his company that knight owns plus get control of almost $800M in cash that he did NOT raise, Goodman did - as this process has unquestionably devalued Goodman's reputation and I am sure he will be working at full potential to restore it and long before his tired grandchildren timeline evolves. When/if he wins, he could do a $2B deal the next day as raising any extra funds would receive widespread market support. Can Jakobsohn claim the same?

Q: How much cash does Gud have compared to its market cap and do they have any growing cash generating product. Thinking of selling position and splitting the proceeds with zynex and viemed.

Q: Like many long suffering investors, I am really getting fed up with this stock. I watched a recent interview on BNN with Jonathan Goodman and was not impressed. He had an opportunity to justify why GUD was a public company and completely failed to do so. His message seemed to be if you are not investing for your grandchildren's financial future you might as well forget this stock. I think GUD should at least initiate an initial and rising dividend policy since it has failed to invest much of the large pool of cash being reserved for acquisitions. What do you think of these odds. Thanks.

Q: Could you explain the differences between these two ETFs, if you can call CGOC an ETF. Specifically as to what they invest in, are they actively managed, and their level of risk compared to each other? Your preference of the two, for someone who has a high risk tolerance, who wishes to have some exposure to the industry?

Q: Hi,

Can I get your opinion on SBIO? It's been treating me pretty well.

Thanks

Q: With the stock up 45% in the last year, would you still consider Merck a buy for a long term hold?

Q: I am tired of waiting for GUD to do something. I have 50,000 shares; what would you suggest in trying to sell these?

Q: Hello,

With the news this morning that Profound Medical's clinical trial proved 96% effective for the prostate cancer patients involved in the study, do you see this as a buy? Or is it still considerably risky, given that FDA approval could take some time or be denied?

Thank you.

Brad

Q: What would you recommend if Mr Goodman steps down? Hold? Sell?
Thank you for your service

Q: I would like your opinion on the company. They seem to have a a fair bit of cash and no debt and would like your opinion if this might be a "speculative" stock to invest in.

Q: please comment on today's quarterly report. thanks

Q: Prometic is refilling an amendment to the BLA for plasminogen in H2 2019. If approved this orphan drug with fast track designation comes with a priority voucher possibly worth 100 million. Lazard has 2 deals to close in H2 as well which depend on approval. That said they need cash badly and announced an eminent debt restructuring. There at 20 cents today. What's your best guess on what happens to the float and share price after this. Do they have to give the company away at these to raise 100 million when possibly 200 million is coming their way this year.

Q: My question is regarding Guardant Health. Would you consider this a good time to buy half a position considering it’s recent massive run up and then sell off? It’s always hard to gauge when to step in after such a drop... but there was finally a good day today there was a ton of volume and the stock was up over 4%. Any reason for the big drop? Was it just because the stock had run up so quickly? I have no issues with risk and have a long time frame. Sector is not a concern either.

Q: What Health Care sector Equites would you recommend, looking for dividend and growth.

Q: hello 5i:
due to the lack of health care companies in Canada, I'm looking to the US. Can you compare the companies above and advise which one you favour?
thanks
Paul L

Q: Hi, What will be the new no. of outstanding shares for Savaria, with 5 mln new shares issued and the insider ownership ( Mr Bouroussa and family, with addition of 71,000 committed from new issue) ? Based on 2019 guidance, and taking into account this dilution, what will be the pay out ratio ? Is this dividend 3.5 cents/month sustainable, in your view ? While no one likes a secondary at $14.15 after an issue at $16.60, a year ago, on a positive note, company could pay down a large portion of $101 mln debt, thus strengthening the balance sheet. Is there a silver lining and stock is worth adding at current level for 3% dividend yield and growth ? Also, is there a lock-in period of 4 months for the new shares from April 22, the expected closing date of secondary? Could it place more pressure on the stock, down the road ? Thank You